Log in

Relevant bibliographies by topics / Zhao xiang qi cai / Journal articles

To see the other types of publications on this topic, follow the link: Zhao xiang qi cai.

Journal articles on the topic 'Zhao xiang qi cai'

Author: Grafiati

Published: 13 December 2022

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 31 journal articles for your research on the topic 'Zhao xiang qi cai.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Huang, Sheng-Zhuo, Fan-Dong Kong, Gao Chen, et al. "A phytochemical investigation of Stemona parviflora roots reveals several compounds with nematocidal activity." Phytochemistry 159 (March 31, 2019): 208–15. https://doi.org/10.1016/j.phytochem.2018.12.021.

Full text

Abstract:

Huang, Sheng-Zhuo, Kong, Fan-Dong, Chen, Gao, Cai, Xiang-Hai, Zhou, Li-Man, Ma, Qing-Yun, Wang, Qi, Mei, Wen-Li, Dai, Hao-Fu, Zhao, You-Xing (2019): A phytochemical investigation of Stemona parviflora roots reveals several compounds with nematocidal activity. Phytochemistry 159: 208-215, DOI: 10.1016/j.phytochem.2018.12.021, URL: http://dx.doi.org/10.1016/j.phytochem.2018.12.021

APA, Harvard, Vancouver, ISO, and other styles

2

Cai, Tong, Shu-Cheng He, Feng-Ming Yu, et al. "Periconia shannanensis sp. nov. (Periconiaceae, Pleosporales) from Xizang, China." Phytotaxa 664, no. 4 (2024): 249–62. https://doi.org/10.11646/phytotaxa.664.4.2.

Full text

Abstract:

Cai, Tong, He, Shu-Cheng, Yu, Feng-Ming, Li, Cui-Jin-Yi, Wang, Zhi-Yang, Ma, Chao, Zhang, Ying, Zhao, Qi (2024): Periconia shannanensis sp. nov. (Periconiaceae, Pleosporales) from Xizang, China. Phytotaxa 664 (4): 249-262, DOI: 10.11646/phytotaxa.664.4.2, URL: https://doi.org/10.11646/phytotaxa.664.4.2

APA, Harvard, Vancouver, ISO, and other styles

3

Qi, Zhi-Hao, Li-Qiong Zeng, Bi Ding, et al. "Taxonomic notes on Anthaxia subgenus Merocratus Bílý from China (Coleoptera: Buprestidae: Buprestinae)." Journal of Natural History 59, no. 5-8 (2025): 253–70. https://doi.org/10.1080/00222933.2024.2438409.

Full text

Abstract:

Qi, Zhi-Hao, Zeng, Li-Qiong, Ding, Bi, Zhan, Fang-Fang, Su, Rong-Xiang, Ai, Hong-Mu, Cai, Shou-Ping, Song, Hai-Tian (2025): Taxonomic notes on Anthaxia subgenus Merocratus Bílý from China (Coleoptera: Buprestidae: Buprestinae). Journal of Natural History 59 (5-8): 253-270, DOI: 10.1080/00222933.2024.2438409, URL: https://doi.org/10.1080/00222933.2024.2438409

APA, Harvard, Vancouver, ISO, and other styles

4

Cai, Chenguang, Xiang Li, Shin-Chen Hou, et al. "Abstract 5552: Novel set of OX40 targeted antibodies and VHHs include agonists and antagonists for future development." Cancer Research 82, no. 12_Supplement (2022): 5552. http://dx.doi.org/10.1158/1538-7445.am2022-5552.

Full text

Abstract:

Abstract Immunotherapy is one of the most effective modern treatments for cancer. While immunotherapy operates through a broad class of mechanisms, modulating immune checkpoints have provided some of the most effective approaches, including inhibition of PD-1/PD-L1 pathway, CTLA-4, LAG-3, OX40, Tim-3, KIR and TIGIT to reverse tumor immune escape.OX40, also known as CD134 or TNFRSF4, is a membrane protein expressed in CD4+ and CD8+ T cells, neutrophils and NK cells. In the process of T cell activation, OX40 plays a synergistic stimulating function by binding with ligand OX40L. OX40 agonist immu

APA, Harvard, Vancouver, ISO, and other styles

5

Lv, Wei-Xiang, Cai-Yun Zhao, and Hong-Zhang Zhou. "One New Species of the Genus Stenus Latreille (Coleoptera, Staphylinidae) from Hubei, China." Zootaxa 4459, no. 1 (2018): 179–87. https://doi.org/10.11646/zootaxa.4459.1.9.

Full text

Abstract:

Lv, Wei-Xiang, Zhao, Cai-Yun, Zhou, Hong-Zhang (2018): One New Species of the Genus Stenus Latreille (Coleoptera, Staphylinidae) from Hubei, China. Zootaxa 4459 (1): 179-187, DOI: 10.11646/zootaxa.4459.1.9

APA, Harvard, Vancouver, ISO, and other styles

6

Lv, Wei-Xiang, Cai-Yun Zhao, and Hong-Zhang Zhou. "Taxonomy of Stenus tenuimargo group (Coleoptera, Staphylinidae, Steninae) with descriptions of two new species from China." Zootaxa 4394, no. 4 (2018): 490–516. https://doi.org/10.11646/zootaxa.4394.4.2.

Full text

Abstract:

Lv, Wei-Xiang, Zhao, Cai-Yun, Zhou, Hong-Zhang (2018): Taxonomy of Stenus tenuimargo group (Coleoptera, Staphylinidae, Steninae) with descriptions of two new species from China. Zootaxa 4394 (4): 490-516, DOI: 10.11646/zootaxa.4394.4.2

APA, Harvard, Vancouver, ISO, and other styles

7

Li, Yaqi, Chengcheng Li, Peng Cui, et al. "Abstract 4567: Circulating tumor DNA-based molecular residual disease guides treatment in metastatic colorectal cancer patients with no evidence of disease: An open-label, prospective, interventional phase II study." Cancer Research 85, no. 8_Supplement_1 (2025): 4567. https://doi.org/10.1158/1538-7445.am2025-4567.

Full text

Abstract:

Abstract Patients with metastatic colorectal cancer (mCRC) can achieve no evidence of disease (NED) after curative treatment. However, the survival benefit of adjuvant chemotherapy (ACT) for these patients remains uncertain. Circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection has shown to help predict recurrence risk in CRC. Recent retrospective studies have indicated that ACT offers no clinical benefit in surgically resected mCRC with negative ctDNA. In this study, we conducted a prospective, interventiaonal clinical trial (NCT05635630) to evaluate the efficacy of c

APA, Harvard, Vancouver, ISO, and other styles

8

Lv, Wei-Xiang, Cai-Yun Zhao, and Hong-Zhang Zhou. "Ta xonomic study on the Chinese Steninae (Coleoptera, Staphylinidae), with descriptions of three new species of the Genus Stenus Latreille." Zootaxa 4429, no. 2 (2018): 247–68. https://doi.org/10.11646/zootaxa.4429.2.2.

Full text

Abstract:

Lv, Wei-Xiang, Zhao, Cai-Yun, Zhou, Hong-Zhang (2018): Ta xonomic study on the Chinese Steninae (Coleoptera, Staphylinidae), with descriptions of three new species of the Genus Stenus Latreille. Zootaxa 4429 (2): 247-268, DOI: 10.11646/zootaxa.4429.2.2

APA, Harvard, Vancouver, ISO, and other styles

9

Zhao, Yue, Jian-Cai Chi, Ya-Ping Chen, et al. "Three new records of Lamiaceae from China and Uzbekistan." Phytotaxa 531, no. 2 (2022): 111. https://doi.org/10.11646/phytotaxa.531.2.3.

Full text

Abstract:

Zhao, Yue, Chi, Jian-Cai, Chen, Ya-Ping, Liang, Cun-Zhu, Turginov, Orzimat T., Pulatov, Sardor O., Rakhmatov, Abdurashid A., Aromov, Tolmas B., Xiang, Chun-Lei (2022): Three new records of Lamiaceae from China and Uzbekistan. Phytotaxa 531 (2): 111-111, DOI: 10.11646/phytotaxa.531.2.3

APA, Harvard, Vancouver, ISO, and other styles

10

Zhao, Ming-Zhi, Zhi-Hao Qi, Rong-Xiang Su, and Tao-Kun Liao. "New and poorly known species of the genus Brachyllus Brenske, 1896 (Coleoptera Scarabaeidae: Melolonthinae) from China." Zootaxa 5256, no. 4 (2023): 358–70. https://doi.org/10.11646/zootaxa.5256.4.4.

Full text

Abstract:

Zhao, Ming-Zhi, Qi, Zhi-Hao, Su, Rong-Xiang, Liao, Tao-Kun (2023): New and poorly known species of the genus Brachyllus Brenske, 1896 (Coleoptera Scarabaeidae: Melolonthinae) from China. Zootaxa 5256 (4): 358-370, DOI: 10.11646/zootaxa.5256.4.4, URL: http://dx.doi.org/10.11646/zootaxa.5256.4.4

APA, Harvard, Vancouver, ISO, and other styles

11

Liao, Zhi-Yu, Rong-Xiang Su, Zhi-Hao Qi, Chen-Sheng Tang, Shou-Ping Cai, and Hai-Tian Song. "Coomaniella sunfengyii sp. nov., a new species from Fujian, China (Coleoptera: Buprestidae: Coomaniellini)." Zootaxa 5318, no. 2 (2023): 275–80. https://doi.org/10.11646/zootaxa.5318.2.7.

Full text

Abstract:

Liao, Zhi-Yu, Su, Rong-Xiang, Qi, Zhi-Hao, Tang, Chen-Sheng, Cai, Shou-Ping, Song, Hai-Tian (2023): Coomaniella sunfengyii sp. nov., a new species from Fujian, China (Coleoptera: Buprestidae: Coomaniellini). Zootaxa 5318 (2): 275-280, DOI: 10.11646/zootaxa.5318.2.7, URL: http://dx.doi.org/10.11646/zootaxa.5318.2.7

APA, Harvard, Vancouver, ISO, and other styles

12

Sun, Ming-Xue, Yan Cui, Yu Li, et al. "Indole alkaloids from Gelsemium elegans." Phytochemistry 162 (June 30, 2019): 232–40. https://doi.org/10.1016/j.phytochem.2019.03.016.

Full text

Abstract:

Sun, Ming-Xue, Cui, Yan, Li, Yu, Meng, Wen-Qi, Xu, Qing-Qiang, Zhao, Jie, Lu, Jin-Cai, Xiao, Kai (2019): Indole alkaloids from Gelsemium elegans. Phytochemistry 162: 232-240, DOI: 10.1016/j.phytochem.2019.03.016, URL: http://dx.doi.org/10.1016/j.phytochem.2019.03.016

APA, Harvard, Vancouver, ISO, and other styles

13

Zhang, Qingyuan, Shusen Wang, Nanlin Li, et al. "Abstract PO1-27-01: Comparing the Efficacy and Safety of TQB2440 versus the Reference Pertuzumab for the Treatment of HER2-Positive Early or Locally Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Parallel-Controlled Phase 3 Trial." Cancer Research 84, no. 9_Supplement (2024): PO1–27–01—PO1–27–01. http://dx.doi.org/10.1158/1538-7445.sabcs23-po1-27-01.

Full text

Abstract:

Abstract Background: Pertuzumab is a recombinant humanized monoclonal antibody targeting the extracellular dimerization domain II of HER2. On September 30, 2013, the FDA have granted accelerated approval of a pertuzumab regimen for neoadjuvant treatment of patients (pts) with high-risk, HER2-positive early stage breast cancer. TQB2440 is a pertuzumab (Perjeta®, Roche) biosimilar. This study aimed to compare the efficacy and safety of TQB2440 and the reference pertuzumab combined with trastuzumab and docetaxel in pts with HER2-positive early or locally advanced breast cancer. Methods: In this m

APA, Harvard, Vancouver, ISO, and other styles

14

Zhu, Chaodong, Arong Luo, Ming Bai, et al. "A joint call for actions to advance taxonomy in China." Zoological Systematics 47, no. 3 (2022): 188–97. https://doi.org/10.11865/zs.2022302.

Full text

Abstract:

Zhu, Chaodong, Luo, Arong, Bai, Ming, Orr, Michael C., Hou, Zhonge, Ge, Siqin, Chen, Jun, Hu, Yibo, Zhou, Xuming, Qiao, Gexia, Kong, Hongzhi, Lu, Limin, Jin, Xiaohua, Cai, Lei, Wei, Xinli, Zhao, Ruilin, Miao, Wei, Wang, Qingfeng, Sha, Zhongli, Lin, Qiang, Qu, Meng, Jiang, Jianping, Li, Jiatang, Che, Jing, Jiang, Xuelong, Chen, Xiaoyong, Gao, Lianming, Ren, Zongxin, Xiang, Chunlei, Luo, Shixiao, Wu, Donghui, Liu, Dong, Peng, Yanqiong, Su, Tao, Cai, Chenyang, Zhu, Tianqi, Cai, Wanzhi, Liu, Xingyue, Li, Hu, Xue, Huaijun, Ye, Zhen, Chen, Xuexin, Tang, Pu, Wei, Shujun, Pang, Hong, Xie, Qiang, Zhang

APA, Harvard, Vancouver, ISO, and other styles

15

Zhu, Di, Fei Ma, Yiqun Li, et al. "Abstract PS8-01: ZN-1041, a potential best-in-class BBB Penetrable HER2 Inhibitor, has high antitumor activity in patients with Breast Cancer with CNS Metastases." Clinical Cancer Research 31, no. 12_Supplement (2025): PS8–01—PS8–01. https://doi.org/10.1158/1557-3265.sabcs24-ps8-01.

Full text

Abstract:

Abstract Background: An estimated 50% of patients with HER2-positive metastatic breast cancer will develop brain metastases (BCBM). BCBM is associated with shortened overall survival and disruption of quality of life, representing an area of investigation for newer and more effective treatments. Previous studies, including Phase 1a and 1b, have demonstrated that ZN-1041, a HER2 TKI designed to penetrate the blood-brain barrier (BBB) with high selectivity and a broad safety margin, exhibits promising antitumor activity both as monotherapy and in combination with trastuzumab and capecitabine. Th

APA, Harvard, Vancouver, ISO, and other styles

16

Cai, Liangliang, Qiang Sun, and Andrew Wee. "On-Surface Synthesis and Coordination Assisted by Computer Version Tools and High-Throughput Techniques." ECS Meeting Abstracts MA2025-01, no. 18 (2025): 1316. https://doi.org/10.1149/ma2025-01181316mtgabs.

Full text

Abstract:

Achieving perfect honeycomb network with large-scale order for molecular systems is technically promising, while remains challenge, where defects and disordering can dramatically affect their performance. The intrinsic topological defects cannot be healed with different preparation parameters owing to the conformational flexibility of the precursor skeleton, which allows the deformation of precursor monomers with limited tension. To address this issue, we adopted a tripod precursor 2,4,6-tris(4-bromophenyl)−1,3,5-triazine (pTBPT), and networks consisting of different membered rings are firstly

APA, Harvard, Vancouver, ISO, and other styles

17

Huang, Yuanyuan, Hangbo Ye, Qingliang Yang, et al. "Abstract 5820: An antibody drug conjugate platform based on novel camptothecin payloads with branch hydrophilic linkers and site-specific conjugation." Cancer Research 84, no. 6_Supplement (2024): 5820. http://dx.doi.org/10.1158/1538-7445.am2024-5820.

Full text

Abstract:

Abstract Antibody-drug conjugates (ADCs) have recently gained momentum as a therapeutic modality for the cell-specific delivery of small molecules beyond their originally-intended purpose of treating cancer. However, the selection of combinations of an optimum target, antibody, payload, linker as well conjugation, to achieve maximal therapeutic efficacy without excessive toxicity, still presents a significant challenge. Topoisomerase I (Topo I) inhibitors such as camptothecin (CPT) analogs represent the much success in ADC payload applications as two CPT analog-ADCs, trastuzumab deruxtecan (DS

APA, Harvard, Vancouver, ISO, and other styles

18

Chen, Zijun, Liqiang Shen, Qi Zhao, et al. "Abstract 4288: Discovery of a small molecule inhibitor of ADAR1 for cancer immunotherapy." Cancer Research 85, no. 8_Supplement_1 (2025): 4288. https://doi.org/10.1158/1538-7445.am2025-4288.

Full text

Abstract:

Adenosine deaminase acting on RNA 1 (ADAR1) is a critical enzyme that catalyzes the conversion of adenosine to inosine in double-stranded RNA (dsRNA). By modifying endogenous dsRNA, ADAR1 prevents erroneous recognition by cytoplasmic dsRNA sensors, including MDA5, PKR, and ZBP1. Inhibition of ADAR1’s deaminase activity can activate MDA5-mediated innate immune responses and stimulate interferon production, while blocking ADAR1’s RNA-binding activity can induce PKR-mediated translational shutdown and cell death. Emerging evidence suggests that silencing ADAR1 enhances tumor responsiveness to imm

APA, Harvard, Vancouver, ISO, and other styles

19

Wang, Bu Hai, Cai Yue Chen, Xian Zhang та ін. "Abstract 5091: The early change of serum interleukin 14α levels predicts the response to anti-PD-1 therapy in cancer". Cancer Research 82, № 12_Supplement (2022): 5091. http://dx.doi.org/10.1158/1538-7445.am2022-5091.

Full text

Abstract:

Abstract Background: Targeting programmed cell death-1 (PD-1) or programmed cell death ligand-1 (PD-L1) has been shown improved clinical efficacy in a wide range of tumor types. We evaluated serum interleukin 14α (IL14α) as a biomarker to predict the response of anti- PD-1 therapy. Patients and methods: Thirty advanced cancer patients treated with PD-1 inhibitor were enrolled in this study. Serum levels of IL-14α were tested at baseline and after 2 cycles of treatment. Result: Among these 30 patients, the mean expression level of IL14α before treatment was 2.1±1.21, whereas the mean level of I

APA, Harvard, Vancouver, ISO, and other styles

20

Yu, Weiwei, Honghong Bao, Shuai Li, et al. "Abstract 5194: BALB/c mice with humanized VISTA: A novel GEMM for preclinical evaluation of therapeutic antibodies against VISTA." Cancer Research 82, no. 12_Supplement (2022): 5194. http://dx.doi.org/10.1158/1538-7445.am2022-5194.

Full text

Abstract:

Abstract VISTA, also known as PD1H, is an immune-checkpoint receptor mainly expressed in immune cells, including macrophages, conventional dendritic cells, monocytes and circulating neutrophils. As a negative regulator of T cell activation, VISTA inhibits T cell proliferation and attenuates the production of cytokines. Studies have shown that VISTA expression is increased in infiltrating immune cells found in the tumor microenvironment and that blocking pathways that lead to VISTA activation can enhance antitumor immune responses in mice. Based on this, antibodies targeting VISTA are promising

APA, Harvard, Vancouver, ISO, and other styles

21

Hobold, Gustavo M., and Betar M. Gallant. "Quantifying Capacity Loss Mechanisms of Li Metal Anodes Beyond Inactive Li⁰." ECS Meeting Abstracts MA2023-01, no. 2 (2023): 630. http://dx.doi.org/10.1149/ma2023-012630mtgabs.

Full text

Abstract:

Lithium metal anodes are promising alternatives to graphite for use in next-generation lithium-ion batteries due to their higher capacity (3,860 mAh/g vs. 372 mAh/g). However, Li anodes still display excessive capacity loss over cycling, leading to underwhelming Coulombic efficiency (CE, <99.9%) compared to graphite (>99.95%).1 These losses can derive from: (1) the formation of electronically isolated Li0 (often referred to as ‘dead’ or inactive’); and (2) the parasitic reactions between Li and the electrolyte that form the solid electrolyte interphase (SEI). Characterization of the Li a

APA, Harvard, Vancouver, ISO, and other styles

22

Guo, Huihui, Zhicang Ye, Yuanyuan Huang, et al. "Abstract 2869: DXC014, a novel bispecific ADC targeting B7-H3 and PSMA, demonstrates favorable antitumor efficacy and safety profiles in preclinical evaluations." Cancer Research 85, no. 8_Supplement_1 (2025): 2869. https://doi.org/10.1158/1538-7445.am2025-2869.

Full text

Abstract:

Abstract B7-H3 (also known as CD276), a member of the B7 ligand family, is overexpressed on differentiated malignant cells and cancer-initiating cells, with limited heterogeneity, and high frequency (60% of 25,000 tumor samples), such as the cells of prostate cancer, non-small cell lung cancer (NSCLC), melanoma, bladder cancer, breast cancer, clear cell renal carcinoma, and head and neck squamous cancer cell (HNSCC), but scarcely detected in normal tissues. PSMA is highly expressed in prostate cancer cells and the endothelial neovasculature of several solid human malignancies. High PSMA expres

APA, Harvard, Vancouver, ISO, and other styles

23

Liu, Guizhong, Zhengxi Dai, Jiagui Qu, et al. "Abstract 2888: Tumor-targeted CD28 bispecific POWERbody࣪ for safe and synergistic T cell-mediated immunotherapy." Cancer Research 82, no. 12_Supplement (2022): 2888. http://dx.doi.org/10.1158/1538-7445.am2022-2888.

Full text

Abstract:

Abstract Targeting CD28 for systemic T cell activation caused severe cytokine storm and multiorgan failure in an anti-CD28 antibody TGN1412 phase 1 trial. However, tumor specific CD28 targeting in a tumor associated antigen (TAA)×CD28 bispecific format, similar to the clinically validated tumor specific CD3 bispecific T-cell engagers (TCEs), offers an attractive solution to mitigate the serious safety concerns associated with systemic CD28 activation while delivering potent T-cell costimulatory signal. Our goal is to combine tumor specific bispecific TCEs targeting both CD3 and CD28, the two e

APA, Harvard, Vancouver, ISO, and other styles

24

Li, Yu-Wei, Ding Ma, Xiang-Rong Wu, et al. "Abstract PS09-09: Multiomics profiling and molecular classification refine precision treatment strategies for HER2-positive breast cancer." Cancer Research 84, no. 9_Supplement (2024): PS09–09—PS09–09. http://dx.doi.org/10.1158/1538-7445.sabcs23-ps09-09.

Full text

Abstract:

Abstract Background: Anti-HER2 targeted therapy has achieved a series of breakthroughs. However, the current treatment strategy regarding HER2-positive breast cancer remains indiscriminate and lacks specificity, which limits the further improvement of overall treatment response and may lead to overtreatment and extra cost for some patients. Our study aims to reveal the molecular heterogeneity of HER2-positive breast cancer to guide a more precise treatment. Patients and methods: We selected HER2-positive breast cancer patients treated at Fudan University Shanghai Cancer Center between 2013 and

APA, Harvard, Vancouver, ISO, and other styles

25

Mazor, Tali, Ino de Bruijn, Rima AlHamad, et al. "Abstract 1249: cBioPortal for Cancer Genomics." Cancer Research 84, no. 6_Supplement (2024): 1249. http://dx.doi.org/10.1158/1538-7445.am2024-1249.

Full text

Abstract:

Abstract cBioPortal for Cancer Genomics is an open-source platform for interactive, exploratory analysis of large-scale clinico-genomic data. cBioPortal provides a suite of user-friendly visualizations and analyses, including OncoPrints, mutation lollipop plots, variant interpretation, group comparison, survival analysis, expression correlation analysis, alteration enrichment analysis, cohort and patient-level visualization. The public site (https://www.cbioportal.org) is accessed by &gt;35,000 unique visitors each month and hosts data from &gt;390 studies spanning individual labs and

APA, Harvard, Vancouver, ISO, and other styles

26

de Bruijn, Ino, Tali Mazor, Rima AlHamad, et al. "Abstract 1117: cBioPortal for cancer genomics." Cancer Research 85, no. 8_Supplement_1 (2025): 1117. https://doi.org/10.1158/1538-7445.am2025-1117.

Full text

Abstract:

Abstract cBioPortal for Cancer Genomics is a widely used platform for exploratory, interactive visualization and analysis of large-scale clinico-genomic datasets. cBioPortal provides a range of visualizations and analyses including interactive cohort exploration, OncoPrints, mutation “lollipop” plots, survival analysis, alteration enrichment analysis, and detailed patient-level visualizations. cBioPortal also integrates variant annotations from a variety of sources to facilitate interpretation. The public cBioPortal (https://www.cbioportal.org) is accessed by &gt;40,000 unique visitors eac

APA, Harvard, Vancouver, ISO, and other styles

27

Bhandari, Sudhir, Ajit Singh Shaktawat, Bhoopendra Patel, et al. "The sequel to COVID-19: the antithesis to life." Journal of Ideas in Health 3, Special1 (2020): 205–12. http://dx.doi.org/10.47108/jidhealth.vol3.issspecial1.69.

Full text

Abstract:

The pandemic of COVID-19 has afflicted every individual and has initiated a cascade of directly or indirectly involved events in precipitating mental health issues. The human species is a wanderer and hunter-gatherer by nature, and physical social distancing and nationwide lockdown have confined an individual to physical isolation. The present review article was conceived to address psychosocial and other issues and their aetiology related to the current pandemic of COVID-19. The elderly age group has most suffered the wrath of SARS-CoV-2, and social isolation as a preventive measure may furth

APA, Harvard, Vancouver, ISO, and other styles

28

黄, 聖松. "楊伯峻《春秋左傳注》考訂四則——以《左傳》成公二年爲範圍". 人文中國學報, 1 травня 2021, 1–24. http://dx.doi.org/10.24112/sinohumanitas.321990.

Full text

Abstract:

LANGUAGE NOTE | Document text in Chinese; abstract also in English. 本文考訂楊伯峻《春秋左傳注》（以下簡稱《左傳注》），以《左傳》成公二年爲範圍，討論“無能爲役”“詰朝”、“朝食”、“大户”四則。經詞例分析，“無能爲役”之“役”當爲名詞，應從《左傳》襄公十七年《春秋左傳集解》（以下簡稱《集解》）釋爲“役事”，較《左傳注》解作“僕役”適洽。《左傳》四見“詰朝”，《集解》於三處釋“平旦”、一處釋“明朝”，《左傳注》解作明日早晨。本文讀“詰”爲“佶”而訓爲“正”，先秦典籍“正”字常有“平”義；至於“朝”與“旦”皆有“早”義，故“詰朝”即“平旦”。《左傳注》謂“朝食”爲早上進食，《史記》則將“朝食”寫爲“會食”。然就《左傳》載齊頃公“余姑翦滅此而朝食”語，顯是自認可在早上結束戰争，故“朝食”仍應解爲在早上進食。《集解》釋“大户”爲“閲民户口”而《左傳注》解作“清理户口”，“大户”之“大”應讀爲“汏”。《説文》謂“汏”字本義爲“淅㶕”，即後世所謂淘洗，沙汏、淘汏皆自“汏”字本義引申。從另一角度言，“淅㶕”亦有清理、計算義；且《左傳》“閲”字亦有“計算”義，故《集解》釋“大户”爲“閲民户口”即計算户籍，乃讀“大”爲“汏”。 This article examines four phrases in Yang Bojun’s C

APA, Harvard, Vancouver, ISO, and other styles

29

Henry, Jacobs. "Xunzi 荀子". Database of Religious History, 27 червня 2024. https://doi.org/10.5281/zenodo.12572692.

Full text

Abstract:

The Xunzi is a work of Early Chinese philosophy that played a key role in consolidating what later became known as Confucian thought. The text is associated with the eponymous figure Xunzi ("Master Xun") - also known by his name Xun Kuang 荀況 or his title Xun Qing 荀卿 ("Minister Xun") - who lived during the Warring States period (453-221 BCE). Defending and critiquing Confucius (trad. 551-479 BCE) and Mencius (371-289 BCE?), the Xunzi is often regarded today as the most sophisticated expression of Early Confucian thought. The recent surge of interest in the Xunzi starkly contrasts the work's mix

APA, Harvard, Vancouver, ISO, and other styles

30

"Acknowledgment of Abstract Reviewers." Circulation 128, suppl_22 (2013). https://doi.org/10.1161/circ.128.suppl_22.a401.

Full text

Abstract:

Abbara, Suhny Abbott, J Dawn Abe, Jun-ichi Abraham, William T. Achenbach, Stephan Ackerman, Michael J. Adabag, Selcuk Adams, Ted Adatya, Sirtaz Ades, Philip A. Ahmed, Bina Aikawa, Elena Ailawadi, Gorav Aizawa, Yoshifusa Aizer, Anthony Akagi, Teiji Akar, Fadi Akhter, Shahab Al Khatib, Sana Al-Ahmad, Amin Al-Mallah, Mouaz Alberts, Mark J. Alexander, John H.. Alexander, Mark Ali, Mo Allen, Larry A. Allen, Norrina B. Allison, Matthew A. Ambrosio, Giuseppe Amsterdam, Ezra Anand, Inder S. Andelfinger, Gregor Anderson, Mark E. Andresen, Brad Antoniucci, David Anversa, Piero Anyanwu, Ani Aon, Miguel A

APA, Harvard, Vancouver, ISO, and other styles

31

Minh, Phan Hong, Vu Khanh Linh, Nguyen Thanh Hai, and Bui Thanh Tung. "A Comprehensive Review of Vaccines against Covid-19." VNU Journal of Science: Medical and Pharmaceutical Sciences 37, no. 3 (2021). http://dx.doi.org/10.25073/2588-1132/vnumps.4365.

Full text

Abstract:

The globe is engulfed by one of the most extensive public health crises as COVID-19 has become a leading cause of death worldwide. COVID-19 was first detected in Wuhan, China, in December 2019, causing the severe acute respiratory syndrome. This review discusses issues related to Covid-19 vaccines, such as vaccine development targets, vaccine types, efficacy, limitations and development prospects. Keywords: Covid-19, SARS-CoV-2, vaccine, spike protein. References [1] C. Wang, P. W. Horby, F. G. Hayden, G. F. Gao, A Novel Coronavirus Outbreak of Global Health Concern, The Lanc

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!